Cargando…

Tumor suppressor miR‐193a‐3p enhances efficacy of BRAF/MEK inhibitors in BRAF‐mutated colorectal cancer

Patients with BRAF‐mutated colorectal cancer (CRC) have a poor prognosis despite recent therapeutic advances such as combination therapy with BRAF, MEK, and epidermal growth factor receptor (EGFR) inhibitors. To identify microRNAs (miRNAs) that can improve the efficacy of BRAF inhibitor dabrafenib (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiraide, Sakura, Takahashi, Masanobu, Yoshida, Yuya, Yamada, Hideharu, Komine, Keigo, Ishioka, Chikashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409311/ https://www.ncbi.nlm.nih.gov/pubmed/34288281 http://dx.doi.org/10.1111/cas.15075

Ejemplares similares

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
por: Takahashi, Hidekazu, et al.
Publicado: (2017)

Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”
por: Hiraide, Sakura, et al.
Publicado: (2021)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
por: Imai, Hiroo, et al.
Publicado: (2020)

Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
por: Saijo, Ken, et al.
Publicado: (2023)

Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer
por: Imai, Hiroo, et al.
Publicado: (2018)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
por: Tian, Jun, et al.
Publicado: (2023)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study
por: Imai, Hiroo, et al.
Publicado: (2022)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities
por: Fleischmann, Jakob, et al.
Publicado: (2023)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia Coli Strain
por: Komine, Keigo, et al.
Publicado: (2015)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma
por: Busch, Elena, et al.
Publicado: (2020)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2drv48ilvitrbkvrf3hbovrv79